Skip Navigation

Currently Enrolling Studies

 If you are interested in participating in any of the following studies, please contact us at (336) 713-8550.  

GB29260 Bronch Study
In this study, we will examine whether or not lebrikizumab reduces the number of white blood cells called eosinophils in the lungs. Eosinophils are a type of body cell that doctors believe plays a part in asthma. The number of eosinophils in the bronchial tubes (also called airways) will be measured in small samples of the lining of the airway in that will be taken at two separate procedures with the use of a small telescope (called a bronchoscope) during the study. This procedure is called bronchoscopy. We also hope to learn what lebrikizumab treatment does to other lung and blood measures that may play a role in asthma. Additionally, we will be testing whether lebrikizumab treatment improves lung function, symptoms, and asthma exacerbations that patients may experience during the study.

Major Requirements:   
          - Current diagnosis of asthma
          - Taking an inhaled corticosteroid medication

Asthma in African Americans (NIH R01)
African Americans are twice as likely to suffer from asthma than other people.  The purpose of this study is to observe overall and lung health in African American/Black people with asthma for a three-year period in order to learn more about the clinical symptoms of asthma in this group over time.  This study also seeks to uncover new information about the specific genes that might influence asthma severity and responses to treatment in African Americans.  There are no interventions in this study.

Major Requirements:  
          - Non-smoker or former smoker
          - African American
          - Current diagnosis of asthma

    Genotype-Phenotype Interaction in Severe Asthma
    The purpose of this project is to study people with severe asthma to try and understand why and how severe asthma develops. This is an observational study only; there are no therapeutic interventions being studied. This study will explore the relationships between clinical symptoms/signs of asthma severity, genes that may influence disease severity and inflammatory substances and cells in the lungs.

    Major Requirements:
              - Current non-smoker
              - Current diagnosis of asthma 

      Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
      The study has two main goals. The first is to find groups of patients with COPD who share certain characteristics. In the future, certain groups might respond better to certain treatments. The second is to find new ways of measuring whether or not COPD is getting worse. This would provide new ways of testing whether a new treatment is working.

      Major Requirements:
                - Current diagnosis of COPD

        Best African American Response to Asthma Drugs (BARD)
        African American/Black children and adults with asthma sometimes don’t get better when they take the usual dose and type of medications like inhaled corticosteroids commonly used to treat asthma.  We want to learn why some African American/Black people with asthma need to take different or more medications than other people.  The purpose of this study is to find the best asthma treatment to add for African American/Black people who have asthma that is not well controlled on a low dose of inhaled steroid. This study will also try to find out if African American/Black adults and children differ in how they respond to the medications used in this study.  

        The study will also try to see if genes (DNA) or, maybe, chemicals in blood, urine or phlegm can predict the response to asthma treatment. It will also study whether the home or work environment might have an effect on responses to asthma treatment. This study will try to see if taking different asthma medications makes economic sense, as well.

        Major Requirements:
                  - African American
                  - Mild to moderate asthma
                  - Asthma must be controlled with medication

          Alendronate for Asthma (ALfa)
          Bronchodilators are inhaled medicines that relax the muscles in the airway. This makes the airway bigger so it is easier to breathe. They also protect against airway narrowing when people are exposed to asthma triggers. One type of bronchodilator is called a beta-2-agonist. Examples are albuterol and salmeterol. When people take beta-2-agonist bronchodilators regularly, the medication may not protect as well against asthma triggers. This is referred to as loss of bronchoprotection. Alendronate is a medication used to prevent and treat certain types of bone loss (osteoporosis). Studies suggest it may prevent the loss of bronchoprotection caused by regular use of beta-2-agonists. The purpose of this study is to find out if alendronate affects the loss of bronchoprotection in patients with asthma who are taking beta-2-agonists.  

          Major Requirements:
                    - Moderate asthma
                    - Taking an inhaled corticosteroid (such as Flovent)

          Beclomethasone Dipropionate in Pediatric Patients with Persistent Asthma (TEVA)
          Teva is sponsoring this research study comparing an investigational drug (one that is not approved by the United States Food and Drug Administration (FDA)) and device combination called Beclomethasone Dipropionate Breath-Actuated Inhaler (BAI) and Beclomethasone Dipropionate Metered-Dose Inhaler (MDI) to placebo (an aerosol that does not contain any active medication) to find out if it is safe and effective in helping children with persistent asthma.

          Major Requirements:
                    - Children 7-11 years old with asthma
                    - Must be on inhaled corticosteroid medication to control asthma
                    - Must be willing to take a placebo
                    - No other major lung diseases

          Steroids in Eosinophil-Negative Asthma (SIENA)
          We know that there are several types of cells that can cause airway inflammation. However, inhaled corticosteroids mostly target only one cell called the eosinophil.  The purpose of this study is to find out if people should take an asthma controller medication based on the type of inflammatory cells present in the airway.  

          Major requirements:
                    - Mild asthma
                    - Not taking inhaled corticosteroids
                    - Must be willing to take a placebo

          Step-Up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations (STICS)
          Most people with asthma use an action plan to guide their asthma treatment. Written asthma action plans are usually color-coded. “Green” means that asthma symptoms are well controlled.  “Yellow” means that asthma symptoms are not well controlled and asthma treatment may need to change. “Red” means a severe worsening of symptoms. Red zone treatment is usually an oral corticosteroid like prednisone. 

          The purpose of this study is to find the best yellow zone action plan strategy for children with asthma. Finding the best yellow zone strategy may prevent children from entering the red zone and having to take prednisone. The study is also trying to determine which yellow zone strategy leads to the least total corticosteroid (oral and inhaled) use for children with asthma.

          Major Requirements:
                    - Children 7-11 years old
                    - Must be on inhaled corticosteroid or combination medication to control asthma



          Quick Reference

          Center for Genomics and Personalized Medicine Research

          Local Phone 336-713-7500
          Toll Free 866-487-2344
          Fax 336-713-7566

          Center for Genomics and Personalized Medicine Research
          Wake Forest School of Medicine
          Medical Center Blvd.
          Winston-Salem, NC  27157
          Find A Doctor Ways to Give
          Last Updated: 04-21-2016
          Wake Forest Baptist Ranked among Nation’s ‘Best Hospitals’  25 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet StatusJoint Commission Report

          Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

          © Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.